J&J unit, Mass. hospital to develop blood test for cancer

Johnson & Johnson ($JNJ) unit Veridex is collaborating with Massachusetts General Hospital to develop and commercialize a next-generation circulating tumor cell (CTC) technology for capturing, counting and characterizing tumor cells found in patients' blood. And researchers hope the test will be used by oncologists as a diagnostic tool aimed at discovering as early as possible if a cancer has spread, as well as by researchers in coming up with new drug therapies. J&J release | Article

Suggested Articles

The immunoassay will measure neurofilament light chain protein levels, found in the blood and cerebrospinal fluid, and linked to nerve damage.

Emmecell aims to make corneal transplant surgery, which can take up to a year to heal from and fails up to 20% of the time, a relic of the past.

Seven developers will provide digital health solutions aimed at the COVID-19 pandemic, including smartphone apps, wearables and big data programs.